Litcius/Paper detail

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

Nicolas Jacquelot, Cyril Seillet, Minyu Wang, Angela Pizzolla, Yang Liao, Soroor Hediyeh-zadeh, Sharon Grisaru‐Tal, Cynthia Louis, Qiutong Huang, Jaring Schreuder, Fernando Souza-Fonseca-Guimarães, Carolyn A. de Graaf, Kevin Thia, Sean Macdonald, Mary Camilleri, Kylie Luong, Shengbo Zhang, Michaël Chopin, Tristan Molden-Hauer, Stephen L. Nutt, Viktor Umansky, Bogoljub Ćirić, Joanna R. Groom, Paul S. Foster, Philip M. Hansbro, Andrew N. J. McKenzie, Daniel H.D. Gray, Andreas Behren, Jonathan Cebon, Éric Vivier, Ian P. Wicks, Joseph A. Trapani, Ariel Munitz, Melissa J. Davis, Wei Shi, Paul J. Neeson, Gabrielle T. Belz

2021Nature Immunology175 citationsDOIOpen Access PDF

Topics & Concepts

Innate lymphoid cellMelanomaCytokineImmune systemImmunologyCancer researchBiologyImmunotherapyInnate immune systemBlockadeTumor microenvironmentCancer immunotherapyReceptorBiochemistryIL-33, ST2, and ILC PathwaysImmune Cell Function and InteractionEosinophilic Esophagitis